NOVARTIS logo.jpg
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
January 31, 2024 01:00 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LRFull year (continuing operations2)Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD)Sales growth was mainly driven by...
NOVARTIS logo.jpg
Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
January 31, 2024 01:00 ET | Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RCExercice complet (activités poursuivies2)Hausse de +10 % (tcc, +8 % USD) du chiffre d’affaires net et de +18 % (tcc, +11 % USD) du...
NOVARTIS logo.jpg
Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen
January 31, 2024 01:00 ET | Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr (fortzuführende Geschäftsbereiche2)Der Nettoumsatz wuchs um +10% (kWk, +8% USD), und das operative Kernergebnis verbesserte sich um +18%...
NOVARTIS logo.jpg
Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia
January 08, 2024 01:15 ET | Novartis Pharma AG
MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid...
NOVARTIS logo.jpg
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
December 11, 2023 01:15 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;...
NOVARTIS logo.jpg
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
December 05, 2023 19:16 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement...
NOVARTIS logo.jpg
Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day
November 28, 2023 01:00 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR  ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent growth ...
NOVARTIS logo.jpg
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
October 30, 2023 02:15 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs. placebo in proteinuria reduction at 36-week interim analysis1;...
NOVARTIS logo.jpg
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
October 24, 2023 01:00 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing...
NOVARTIS logo.jpg
Novartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöht
October 24, 2023 01:00 ET | Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Die Transformation zu einem Unternehmen, das rein auf innovative Medikamente spezialisiert ist, wurde mit dem Spin-off von Sandoz abgeschlossen; die...